Application Effect of Bevacizumab Combined with Chemotherapy in Advanced Colorectal Cancer Patients and Its Impact on Immune Levels
Objective:To analyze the effect of Bevacizumab combined with chemotherapy on patients with advanced colorectal cancer and the impact on immune level.Method:The clinical data of 60 patients with advanced colorectal cancer admitted to the Oncology Ⅰ Department of Yangjiang People's Hospital from January 2022 to January 2023 were retrospectively analyzed,and they were divided into two groups according to different treatment plans,with 30 cases in each group.The control group was treated with Oxaliplatin combined with Capecitabine(XELOX)chemotherapy regimen,and the observation group was treated with Bevacizumab based on the control group.The clinical efficacy,tumor markers,immune indexes and incidence of adverse reactions between the two groups were compared.Result:The objective response rate(ORR)of the observation group was 60.00%,which was higher than 33.33%of the control group,the difference was statistically significant(P<0.05).After intervention,carcinoembryonic antigen(CEA),serum amyloid A(SAA)and carbohydrate antigen 19-9(CA19-9)in two groups were lower than those before intervention,and those in the observation group were lower than those in the control group,the differences were statistically significant(P<0.05).After intervention,CD3+,CD4+and CD4+/CD8+in both groups were lower than those before intervention,and CD8+was higher than that before intervention,but CD3+,CD4+and CD4+/CD8+in observation group were higher than those in control group,and CD8+was lower than that in control group,the differences were statistically significant(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion:Compared with XELOX chemotherapy alone,XELOX chemotherapy combined with Bevacizumab can improve the clinical effective rate,reduce the level of tumor markers,improve the level of T lymphocyte immunity in patients with advanced colorectal cancer,and do not increase the incidence of adverse reactions.
万方数据
维普
